BR112021026411A2 - Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos - Google Patents

Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos

Info

Publication number
BR112021026411A2
BR112021026411A2 BR112021026411A BR112021026411A BR112021026411A2 BR 112021026411 A2 BR112021026411 A2 BR 112021026411A2 BR 112021026411 A BR112021026411 A BR 112021026411A BR 112021026411 A BR112021026411 A BR 112021026411A BR 112021026411 A2 BR112021026411 A2 BR 112021026411A2
Authority
BR
Brazil
Prior art keywords
lrrc25
compositions
methods
myeloid cell
cell phenotypes
Prior art date
Application number
BR112021026411A
Other languages
English (en)
Inventor
Brian O'nuallain
Igor Feldman
A Wahle Joseph
L Sazinsky Stephen
I Novobrantseva Tatiana
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of BR112021026411A2 publication Critical patent/BR112021026411A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos. a presente invenção refere-se, em parte, à descoberta de uma composição anti-lrrc25 (por exemplo, anticorpos monoclonais e fragmentos de ligação ao antígeno dos mesmos), que regulam fenótipos inflamatórios de células mieloides, tais como células mieloides supressoras, monócitos, macrófagos, neutrófilos e/ou células dendríticas, incluindo polarização, ativação e/ou função, e a métodos de uso dessas composições anti-lrrc25 para propósitos terapêuticos, diagnósticos, prognósticos e de triagem.
BR112021026411A 2019-06-27 2020-06-17 Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos BR112021026411A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867593P 2019-06-27 2019-06-27
PCT/US2020/038115 WO2020263650A1 (en) 2019-06-27 2020-06-17 Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (1)

Publication Number Publication Date
BR112021026411A2 true BR112021026411A2 (pt) 2022-03-15

Family

ID=74060354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026411A BR112021026411A2 (pt) 2019-06-27 2020-06-17 Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos

Country Status (10)

Country Link
US (1) US20220363752A1 (pt)
EP (1) EP3990017A4 (pt)
JP (1) JP2022539038A (pt)
KR (1) KR20220042131A (pt)
CN (1) CN114423452A (pt)
AU (1) AU2020306772A1 (pt)
BR (1) BR112021026411A2 (pt)
CA (1) CA3142838A1 (pt)
IL (1) IL289166A (pt)
WO (1) WO2020263650A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077170A1 (en) * 2022-10-05 2024-04-11 Shangpharma Innovation, Inc. Anti-urokinase-type plasminogen activator receptor antibodies and methods of use
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10279018B2 (en) * 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
EP3311173A2 (en) * 2015-06-18 2018-04-25 Thomas Mole Herd Methods of characterising cancer
WO2017004153A1 (en) * 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
BR112018076005A2 (pt) * 2016-06-14 2019-03-26 Advanced Biodesign anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral
CA3030841A1 (en) * 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
TW202023629A (zh) * 2018-06-29 2020-07-01 美商維西歐製藥公司 用於調節單核球及巨噬細胞發炎表型之組合物及方法以及其免疫療法用途

Also Published As

Publication number Publication date
IL289166A (en) 2022-02-01
CA3142838A1 (en) 2020-12-30
US20220363752A1 (en) 2022-11-17
CN114423452A (zh) 2022-04-29
KR20220042131A (ko) 2022-04-04
EP3990017A1 (en) 2022-05-04
EP3990017A4 (en) 2023-04-26
AU2020306772A1 (en) 2022-02-17
WO2020263650A1 (en) 2020-12-30
JP2022539038A (ja) 2022-09-07

Similar Documents

Publication Publication Date Title
BR112021024314A2 (pt) Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
WO2022109339A8 (en) Use of dextramer in single cell analysis
BR112021008930A2 (pt) Métodos e combinações para o tratamento e modulação de célula t
BR112021026411A2 (pt) Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112021026181A2 (pt) Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
WO2020096631A3 (en) Compositions, methods and systems for protein corona analysis and uses thereof
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
WO2018115017A3 (en) CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
Huynh et al. CSF-1 receptor signalling from endosomes mediates the sustained activation of Erk1/2 and Akt in macrophages
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112021024242A2 (pt) Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112018067479A2 (pt) anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo
BR112022023892A2 (pt) Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
MX2021012769A (es) Anticuerpos bloqueadores cd73.
MX2022005091A (es) Metodos de preparacion de una muestra enriquecida para la secuenciacion de polipeptidos.
MX2021001395A (es) Arni variante contra alfa-sinucleína.
MX2022007706A (es) Anticuerpos utiles en diagnosis de cancer.